Overview of HuScan™, VirScan™, & XenScan™ PhIP-Seq.
Bacteriophage Immunoprecipitation Sequencing (PhIP-Seq) is a powerful new method of multiplexed analysis that combines DNA high-throughput sequencing with next-generation proteomics. PhIP-Seq allows researchers to determine what antibodies were created by an individual’s unique history of immune exposures. Our PhIP-Seq assay is the highest-coverage antigen-specific assay ever developed, able to detect antibodies versus every known human protein or virus as overlapping long peptides.
PhIP-Seq was developed at Harvard University by CDI Scientific Advisory Board member Ben Larman, Steve Elledge, and colleagues in 2011. This work created HuScan™, a synthetic representation of the complete human proteome as a T7 bacteriophage display library. They built upon this work in 2015, by creating VirScan™, a synthetic representation of the complete human virome: the universe of known infectious viruses.
Since then, PhIP-Seq has been used to perform revolutionary immune profiling on people suffering from measles, multiple sclerosis, diabetes, rheumatoid arthritis, and more. By sequencing millions of DNA strands at once, CDI’s PhIP-Seq is a powerful technology that helps scientists determine the immune system’s role in complex disease non-invasively, quickly, and at a low cost.
Creation of the XenScan™ Immune Epitope Database (IEDB) xenoantigen profiling assay was first reported alongside an updated VirScan™ library. This library contains every full-length UniProt protein with an IEDB-curated antigen that does not originate from humans, viruses, or malaria (plasmodium).